SecBot SecBot
Insider Cluster (2 insiders) ·Filed Aug 12, 2026

MIRM

Mirum Pharmaceuticals, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed3mo ago
Insider cluster: 2 insiders, $1.8M total
Actionable Insight • Neutral

The insider sales are routine post-earnings cashless option exercises by the CEO and a small CFO sale, the dollar amounts are trivial relative to market cap and carry no bearish signal. Monitor for any 10b5-1 plan disclosures or additional insider sales in the next 30 days, but this cluster alone does not warrant action. The more material event is the volixibat pipeline delay from the Aug 5 earnings release.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$98.77
T+0 close · Aug 12, 2026 · via day close
Latest settled
−5.11%
T+60 · $93.72
Vs SPY
+0.36%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 13 $98.77entry
  2. T+1 · 3mo ago +1.89%α +2.09% · $100.64
  3. T+5 · 3mo ago −1.61%α +0.35% · $97.18
  4. T+20 · 2mo ago −0.56%α +1.19% · $98.22
  5. T+60 · 11d ago −5.11%α +0.36% · $93.72
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mirum Pharmaceuticals CEO Christopher Peetz and CFO Eric Bjerkholt sold a combined $1.75M in open-market stock within two days of the company's Q2 2026 earnings release, which showed strong 38% revenue growth but a significant GAAP EPS miss (-$1.06 vs -$0.75 consensus) and a key pipeline delay for volixibat. The CEO's sales ($1.98M total, including derivative exercises) and CFO's sale ($600K) represent ~0.03% of the $6.4B market cap, a trivial proportion that is likely liquidity-driven following option exercises rather than a bearish signal. The cluster is a net sell but the dollar amount is immaterial relative to company size, and the CEO's derivative exercise and same-day sale is a classic cashless exercise pattern, not an informed sell signal.

Key Financial Metrics

Direction
selling
Total Value
$2.5M
Insiders
2

Key Facts

  • CEO Peetz sold 20,000 shares via derivative exercise and open-market sales totaling ~$1.98M on Aug 10
  • CFO Bjerkholt sold 6,001 shares for ~$600K on Aug 11
  • Total cluster open-market sales: ~$2.55M (including CEO's derivative exercise cost of $58,720)
  • Sales represent ~0.04% of MIRM's $6.4B market cap, well below the 0.1% materiality threshold
  • Cluster occurred 5-6 days after Q2 earnings (Aug 5) which showed 38% revenue growth but a GAAP EPS miss and volixibat delay
  • CEO's trades include a same-day derivative exercise and sale, consistent with a cashless stock option exercise pattern

Financial Impact

Total open-market sales of ~$2.55M represent ~0.04% of market cap, immaterial

insider ownershipdilution

Risk Factors

  • Pipeline setback for volixibat (NDA delayed to H1 2027 after FDA recommended Phase 3 study)
  • GAAP EPS miss (-$1.06 vs -$0.75 consensus) driven by heavy R&D/SG&A spending
  • CEO and CFO both selling post-earnings could be perceived negatively by retail investors despite trivial size

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-MIRM-1786608259408

US Market Status

Market Closed · Opens in 8h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026